<h4>Background</h4>This is the first case report describing a patient with non-small cell lung cancer (NSCLC) harboring two rare human epidermal growth factor receptor 2 (HER2) exon 21 insertion mutations, who responded to furmonertinib treatment. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.